CN115774066B - Method for analyzing component proportion of ultra-low molecular weight hyaluronic acid - Google Patents
Method for analyzing component proportion of ultra-low molecular weight hyaluronic acid Download PDFInfo
- Publication number
- CN115774066B CN115774066B CN202211465206.2A CN202211465206A CN115774066B CN 115774066 B CN115774066 B CN 115774066B CN 202211465206 A CN202211465206 A CN 202211465206A CN 115774066 B CN115774066 B CN 115774066B
- Authority
- CN
- China
- Prior art keywords
- hyaluronic acid
- molecular weight
- mobile phase
- low molecular
- ultra
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 44
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 44
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims abstract description 11
- 238000010828 elution Methods 0.000 claims abstract description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000005571 anion exchange chromatography Methods 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 19
- 108010003272 Hyaluronate lyase Proteins 0.000 claims description 6
- 102000001974 Hyaluronidases Human genes 0.000 claims description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 229960002773 hyaluronidase Drugs 0.000 claims description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 6
- 235000011152 sodium sulphate Nutrition 0.000 claims description 6
- FWFGVMYFCODZRD-UHFFFAOYSA-N oxidanium;hydrogen sulfate Chemical compound O.OS(O)(=O)=O FWFGVMYFCODZRD-UHFFFAOYSA-N 0.000 claims description 5
- 241000545744 Hirudinea Species 0.000 claims description 3
- 150000002016 disaccharides Chemical class 0.000 claims description 3
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 2
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims description 2
- 229910052939 potassium sulfate Inorganic materials 0.000 claims description 2
- 235000011151 potassium sulphates Nutrition 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- 150000004044 tetrasaccharides Chemical class 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 14
- 238000004458 analytical method Methods 0.000 abstract description 13
- 239000000203 mixture Substances 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- 239000011159 matrix material Substances 0.000 abstract description 3
- 230000005526 G1 to G0 transition Effects 0.000 abstract description 2
- 229920001542 oligosaccharide Polymers 0.000 description 18
- 239000012488 sample solution Substances 0.000 description 14
- 150000002482 oligosaccharides Chemical class 0.000 description 13
- 238000000926 separation method Methods 0.000 description 9
- 229920002385 Sodium hyaluronate Polymers 0.000 description 7
- 229940010747 sodium hyaluronate Drugs 0.000 description 7
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- -1 hyaluronic acid oligosaccharide Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004811 liquid chromatography Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000337 buffer salt Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 229920000768 polyamine Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 125000000600 disaccharide group Chemical group 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019837 monoammonium phosphate Nutrition 0.000 description 1
- 239000006012 monoammonium phosphate Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940038384 octadecane Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to analysis of the component ratio in ultra low molecular weight hyaluronic acid by anion exchange chromatography employing a ZORBAX SAX column or a Spherisorb SAX column; the gradient elution was performed using a mobile phase consisting of water and aqueous sulfate. The analysis method can avoid the interference of the matrix on detection, and simultaneously the stationary phase has lower price, thus greatly saving the cost; the composition of the used mobile phase is common, the preparation is simple, and the trouble and the labor are saved; the mobile phase has short running time and time-saving and convenient operation, so the analysis method is suitable for popularization and application.
Description
Technical Field
The invention relates to the technical field of biology, in particular to an analysis method of the component proportion of ultra-low molecular weight hyaluronic acid.
Background
Hyaluronic Acid (HA), a macromolecular Hyaluronic acid, is an acidic linear polysaccharide formed by repeated arrangement of disaccharides of (1-3) -2-N-acetamido-2-deoxy-D-glucose- (1-4) -O- β -D-glucuronic acid. The natural moisturizing factor is obtained by first extracting from bovine vitreous body in 1934 by Meyer et al, HAs strong hydrophilicity and good moisturizing performance, is a substance with the best moisturizing performance found in the nature at present, is recognized as the most ideal natural moisturizing factor by the international cosmetic industry, and is widely applied to industries of cosmetics, foods, medicines and the like because HA HAs no immunogenicity and toxicity.
According to the research in the literature, it is shown that hyaluronic acid with molecular weight lower than 1×10 4, commonly called hyaluronic acid oligosaccharide or hyaluronic acid oligosaccharide (o-HA) or low molecular weight hyaluronic acid, shows very strong biological activity and HAs the functions of promoting wound healing, promoting bone and angiogenesis, regulating immunity, etc. Besides the medicine field, o-HA can enter the skin for deep moisture preservation through percutaneous absorption due to extremely small molecular weight, and the synthetic precursor of HA in the body is increased, so that the o-HA HAs wide application prospect in the cosmetic field and the food field.
The products obtained by enzymatic hydrolysis of hyaluronic acid are generally mixtures of various o-HA, which must be isolated if o-HA of different sugar residue numbers is to be prepared. Meanwhile, the structure of the obtained low molecular weight hyaluronic acid is different due to different types of the hyaluronidase. For example, bovine testis hyaluronidase is capable of hydrolyzing beta-1, 4 glycosidic bond in HA to produce oligosaccharide series with reducing end as glucosamine, and the minimum product is disaccharide (GlcUA-GlcNAc); the leech type hyaluronidase can hydrolyze beta-1, 3 glycosidic bonds in HA to generate a saturated oligosaccharide series with the reducing end of glucuronic acid; the final product obtained by endo-beta-1, 4 glycosidic linkage and beta-elimination of the microbial hyaluronidase is a single 4, 5-unsaturated disaccharide. Therefore, for different oligosaccharides, the analysis and detection methods are not necessarily universal due to different molecular structures, and the separation degree between different components needs to be considered at the same time.
The analytical detection methods currently used for comparison are gel chromatography and ion exchange. The gel chromatography can only obtain a hyaluronic acid oligosaccharide mixture with a certain molecular weight range, can not prepare O-HA with single molecular weight, and HAs the advantages of high price, short service life, quick loss and poor reproducibility. In addition, lv Mengxian et al (preparation of tetraose and hexaose of hyaluronic acid and study of biological activity [ D ],2016, university of Jiangnan) disclose the use of YMC-Pack Polyamine II amino group hydrophilization chromatographic column and the use of sodium chloride or monoammonium phosphate as mobile phase for separation detection, but under such conditions, the peak-to-peak type of the chromatography is easily bad, the separation effect is bad, the reproducibility is bad, the chromatographic column itself has the problem of short service life, and the column efficiency starts to be seriously reduced after about 10 needles are introduced. CN109517012B discloses that Sepax HP-SAX is used for separating hyaluronic acid oligosaccharide, and is mainly used for preparing high-purity hyaluronic acid oligosaccharide, and the mobile phase of the method has fast flow rate, long running time, poor separation effect, unstable chromatographic baseline like baseline up-shift, and is not suitable for analysis and detection.
Therefore, the development of the analysis method for detecting the low molecular weight hyaluronic acid component proportion has the advantages of lower cost, more use times, short running time, stable chromatographic baseline, good chromatographic peak-to-peak type and good reproducibility, and has wide application prospect and important significance.
Disclosure of Invention
The invention aims to provide a method for analyzing the component proportion of ultra-low molecular weight hyaluronic acid, which has the advantages of lower cost, more use times, short running time, stable chromatographic baseline, good chromatographic peak-to-peak type property and better reproducibility, meets the separation and detection requirements of oligosaccharide substances in the biotechnology field, and solves the problems of short service life, high price and poor reproducibility of the chromatographic method of the chromatographic column in the prior art.
In the present invention, low molecular weight hyaluronic acid having a molecular weight of less than 1200Da is referred to as ultra-low molecular weight hyaluronic acid.
In order to achieve the above object, the present invention provides a method for analyzing the component ratio of ultra-low molecular weight hyaluronic acid by anion exchange chromatography using ZORBAX SAX column or Spherisorb SAX column and gradient eluting with a mobile phase composed of water and sulfate aqueous solution.
The invention adopts ZORBAX SAX chromatographic column or Sphermsorb SAX chromatographic column, and the peak-out sequence is disaccharide, tetraose, hexaose, octaose, decaose, dodecaose, tetradecose, hexadecose, octadecane, etc. according to the molecular weight from small to large, and has the advantages of low price, reducing the interference caused by impurities to detection, etc.
When the invention adopts the mobile phase composed of water and sulfate water solution to carry out gradient elution, better peak shape can be obtained, and the matrix interference can be reduced.
As an embodiment of the present invention, the aqueous sulfate solution includes one of an aqueous sodium sulfate solution, an aqueous potassium sulfate solution, or an aqueous ammonium sulfate solution.
As one embodiment of the invention, the pH value of the sulfate aqueous solution in the mobile phase is 3.0-6.5, which shows that the pH tolerance range is wide under the method. Because bacteria grow easily under the partial neutral condition, the pH of the sulfate aqueous solution is preferably 3.0 to 4.0, such as more specifically 3.5.
As one embodiment of the invention, the concentration of the sulfate aqueous solution in the mobile phase is 50-100mM, and the good separation of the oligosaccharide components in the ultra-low molecular weight hyaluronic acid can be realized under the condition of lower concentration of the buffer salt (such as less than or equal to 100 mM) in the mobile phase system of the invention relative to other buffer salts such as sodium chloride or sodium hydrogen phosphate.
As one embodiment of the invention, the flow rate of the mobile phase is 0.5-2.0ml/min. Within this flow rate range, the peaks of the components can be separated effectively without significant differences. The flow rate is preferably 1.0ml/min in combination with the mobile phase consumption and the pressure. When the flow rate is too high, the retention time of each component of the oligosaccharide is shortened, and the oligosaccharide is likely to be interfered by other solvent peaks or impurity peaks; when the flow rate is too low, the running time of the mobile phase is long, and the labor cost is increased.
As an implementation mode of the invention, the mobile phase adopts a gradient elution mode, and the volume ratio of water to sulfate water solution is 95-0 within 0-40 min: 5-100. Within this gradient range, for example 0-25min,0-30min,0-40min, the volume ratio of water to aqueous sulfate solution is 95-0: and 5-100, performing linear gradient elution, wherein the peak-to-average of each component can be effectively separated without obvious difference. In combination with the baseline and acquisition time, the volume ratio of water to aqueous sulfate solution is preferably 95:5.
As an embodiment of the present invention, the mobile phase has a run time of 30 to 40 minutes. Compared with other buffer salts such as sodium chloride or sodium hydrophosphate, the chromatographic system of the invention has the advantages of greatly shortened running time and labor cost saving.
As one embodiment of the present invention, the column temperature of the chromatographic column is 30-40 ℃, such as 40 ℃. In the column temperature range, the peak separation trend of each component is consistent, no obvious difference exists, and the column temperature tolerance range is wide under the method.
As one embodiment of the invention, the ultra-low molecular weight hyaluronic acid is obtained by enzymolysis of macromolecular hyaluronic acid in a leech type hyaluronidase, and the structural general formula of the ultra-low molecular weight hyaluronic acid is shown as the following formula I:
formula I: n=0 to 10, x=h, K or Na.
As one embodiment of the present invention, after analyzing the ratio of the components in the ultra-low molecular weight hyaluronic acid by anion exchange chromatography, the peaks of the respective components in the analysis method of the present invention may be confirmed by locating them by LC-MS or HRMS or other methods.
Compared with the prior art, the analysis and detection method has the advantages that: the component proportion of the ultra-low molecular weight hyaluronic acid is analyzed by anion exchange chromatography, wherein the anion exchange chromatography adopts a ZORBAX SAX chromatographic column or a Spheresorb SAX chromatographic column, so that the interference of a matrix on detection can be avoided, and meanwhile, the price of a stationary phase is lower, so that the cost can be greatly saved; the mobile phase composed of water and sulfate water solution is adopted for gradient elution, and the mobile phase used in the analysis method has common composition, simple preparation and labor saving; the running time of the mobile phase is short, so that the analysis time is short, and the operation is time-saving and convenient. The analysis method of the invention has the advantages of rapidness, simplicity, convenience, lower cost, more use times, short running time, stable chromatographic baseline, good chromatographic peak-to-peak type and better reproducibility, and is suitable for popularization and application.
Drawings
FIG. 1 is a liquid chromatography obtained according to example 1.
Fig. 2 is a liquid chromatography chart obtained according to example 2.
Fig. 3 is a liquid chromatography chart obtained according to example 3.
Fig. 4 is a liquid chromatography chart obtained according to example 4.
FIG. 5 is a liquid chromatograph obtained according to comparative example 1.
FIG. 6 is a liquid chromatography obtained according to comparative example 2.
Detailed Description
The ultra-low molecular weight hyaluronic acid used in the examples, including sodium hyaluronate sample solution hydrolyzed for 7h and sodium hyaluronate sample solution hydrolyzed for 15h, were all provided by Nanjing Letaau biosciences, inc., the preparation process of which was referred to in the present company as applied for Chinese patent application No. CN202211086464.X, the entire contents of which were incorporated herein by reference.
The equipment or other reagents/materials used in the examples are commercially available.
Example 1
(1) Experimental conditions:
The device comprises: agilent high performance liquid chromatograph.
Chromatographic column: ZORBAX SAX 250 mm. Times.4.6 mm,5 μm.
Mobile phase: mobile phase a was purified water, mobile phase B was 100mM sodium sulfate (ph=3.5), and gradient elution.
The gradients are shown in table 1 below:
TABLE 1 Mobile phase gradient Table
| Time (min) | A％ | B％ |
| 0 | 95 | 5 |
| 30 | 0 | 100 |
| 31 | 0 | 100 |
| 32 | 95 | 5 |
| 39 | 95 | 5 |
The flow rate is 1.0mL/min, the column temperature is 40 ℃, the sample injection amount is 25 mu L, and the detection wavelength is 210nm.
(2) Results: the specific pattern is shown in figure 1, and each component can be effectively separated and detected.
Meanwhile, the service life of the chromatographic column is counted, and it is found that at least about 50 needle samples (after a sodium hyaluronate sample solution hydrolyzed for 15 hours is added with a proper amount of water and mixed uniformly, an ultra-low molecular weight hyaluronic acid solution with the concentration of 5 mg/ml) can be detected, and the higher column efficiency can be maintained. The service life of the chromatographic column is about 5 times of that of other types of chromatographic columns reported in the prior art, and the consumable cost is greatly saved.
Example 2
(1) Experimental conditions:
the device comprises: waters high performance liquid chromatograph.
Chromatographic column: sphermsorb SAX 4.6 mm. Times.250 mm,5 μm.
Mobile phase: mobile phase a was purified water, mobile phase B was 100mM sodium sulfate (ph=3.5), and gradient elution.
The gradients are shown in table 1 below:
TABLE 1 Mobile phase gradient Table
| Time (min) | A％ | B％ |
| 0 | 95 | 5 |
| 30 | 0 | 100 |
| 31 | 0 | 100 |
| 32 | 95 | 5 |
| 39 | 95 | 5 |
The flow rate is 1.0mL/min, the column temperature is 40 ℃, the sample injection amount is 25 mu L, and the detection wavelength is 210nm.
(2) Results: the specific pattern is shown in figure 2, and each component can be effectively separated and detected.
Meanwhile, the service life of the chromatographic column is counted, and at least about 80 samples (after a sodium hyaluronate sample solution hydrolyzed for 15 hours is added with a proper amount of water and mixed uniformly, an ultra-low molecular weight hyaluronic acid solution with the concentration of 5 mg/ml) can be detected, so that the higher column efficiency can be maintained. The service life of the chromatographic column is about 8 times of that of other types of chromatographic columns reported in the prior art, and the consumable cost is greatly saved.
Example 3
The device comprises: agilent high performance liquid chromatograph.
Chromatographic column: ZORBAX SAX 250 mm. Times.4.6 mm,5 μm.
Mobile phase: mobile phase a was purified water, mobile phase B was 50mM sodium sulfate (ph=3.0), and gradient elution.
The gradients are shown in table 1 below:
TABLE 1 Mobile phase gradient Table
| Time (min) | A％ | B％ |
| 0 | 95 | 5 |
| 40 | 0 | 100 |
| 41 | 95 | 5 |
| 49 | 95 | 5 |
The flow rate is 0.5mL/min, the column temperature is 35 ℃, the sample injection amount is 25 mu L, and the detection wavelength is 210nm.
The obtained specific pattern is shown in figure 3, and each component can be effectively separated and detected.
Example 4
The device comprises: agilent high performance liquid chromatograph.
Chromatographic column: ZORBAX SAX 250 mm. Times.4.6 mm,5 μm.
Mobile phase: mobile phase a was purified water and mobile phase B was 80mM sodium sulfate (ph=6.5), gradient elution.
The gradients are shown in table 1 below:
TABLE 1 Mobile phase gradient Table
| Time (min) | A％ | B％ |
| 0 | 95 | 5 |
| 25 | 0 | 100 |
| 26 | 95 | 5 |
| 34 | 95 | 5 |
The flow rate is 2.0mL/min, the column temperature is 30 ℃, the sample injection amount is 25 mu L, and the detection wavelength is 210nm.
The obtained specific pattern is shown in figure 4, and each component can be effectively separated and detected.
Example 5
The present embodiment performs a specific methodological verification of the provided method.
The method specificity was examined using the sample solution 1 (containing) and the sample solution 2, and the results are shown in table 1 below. Wherein the sample solution 1 is prepared by mixing sodium hyaluronate sample solution hydrolyzed for 7h with proper amount of water to obtain ultra-low molecular weight hyaluronic acid solution with concentration of 5 mg/ml. The sample solution 2 is prepared by mixing sodium hyaluronate sample solution hydrolyzed for 15h with proper amount of water to obtain ultra-low molecular weight hyaluronic acid solution with concentration of 5 mg/ml.
TABLE 1 results of specific experiments
The results show that the peak purity of each component is greater than 980, which indicates that the method has good specificity.
Example 6
The present example performs repeated methodological validation of the provided method.
The contents of the respective components in 6 parts of the ultra-low molecular weight hyaluronic acid test sample solutions arranged in parallel were examined, and the results are shown in table 2 below. Wherein the concentration of the sample solution is 5mg/ml, and the sample solution is obtained by adding a proper amount of water into a sodium hyaluronate sample solution hydrolyzed for 15 hours and uniformly mixing.
TABLE 2 repeatability test results
The results show that the Relative Standard Deviation (RSD) of the area percentage of each component peak is far less than 5%, so the repeatability of the method is good.
Comparative example 1
The ZORBAX SAX column of example 1 was replaced with YMC-Pack Polyamine II column, and the conditions were the same as in example 1, and the specific spectrum obtained was shown in FIG. 5.
The results show that under the YMC-Pack Polyamine II chromatographic conditions, the separation effect is poor, the chromatographic peak type is poor, and the reproducibility is poor. The chromatographic column has the problem of short service life, and the column effect begins to be seriously reduced after about 10 needles are injected.
Comparative example 2
The ZORBAX SAX column of example 1 was replaced with Sepax HP-SAX column, and the conditions were the same as in example 1, and the specific pattern obtained was shown in FIG. 6.
The results show that under the Sepax HP-SAX chromatographic condition, the separation effect is poor, the main peak of the oligosaccharide component is easily interfered by other solvent peaks and impurity peaks, the chromatographic base line is easily moved upwards, and the method is not suitable for analysis and detection.
Claims (5)
1. A method for analyzing the proportion of an ultra-low molecular weight hyaluronic acid component, characterized by: analyzing the component proportion of the ultra-low molecular weight hyaluronic acid by anion exchange chromatography, wherein the anion exchange chromatography adopts a ZORBAX SAX chromatographic column or a Spheresorb SAX chromatographic column, and adopts a mobile phase composed of water and sulfate water solution for gradient elution;
the pH value of the sulfate aqueous solution in the mobile phase is 3.0-6.5;
The concentration of the sulfate aqueous solution in the mobile phase is 50-100mM;
the mobile phase adopts a gradient elution mode, and the volume ratio of water to sulfate water solution is 95:5-0:100 within 0-40 min;
the ultra-low molecular weight hyaluronic acid is obtained by enzymolysis of macromolecular hyaluronic acid in a leech type hyaluronidase, and the structural general formula of the ultra-low molecular weight hyaluronic acid is shown as the following formula I:
; formula I: n=0 to 10, x=h, K or Na;
The components comprise disaccharides, tetrasaccharides, hexasaccharides, octasaccharides, decasaccharides, dodecasaccharides, tetradecsaccharides, hexadecsaccharides and octadecanoates.
2. The method according to claim 1, characterized in that: the aqueous sulfate solution comprises one of an aqueous sodium sulfate solution, an aqueous potassium sulfate solution or an aqueous ammonium sulfate solution.
3. The method according to claim 1, characterized in that: the flow rate of the mobile phase is 0.5-2.0ml/min.
4. The method according to claim 1, characterized in that: the column temperature of the chromatographic column is 30-40 ℃.
5. The method according to claim 1, characterized in that: the ultra-low molecular weight hyaluronic acid has an average molecular weight of less than 1200 daltons.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022114331080 | 2022-11-16 | ||
| CN202211433108 | 2022-11-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115774066A CN115774066A (en) | 2023-03-10 |
| CN115774066B true CN115774066B (en) | 2024-08-27 |
Family
ID=85389700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211465206.2A Active CN115774066B (en) | 2022-11-16 | 2022-11-22 | Method for analyzing component proportion of ultra-low molecular weight hyaluronic acid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115774066B (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100369925C (en) * | 2000-07-07 | 2008-02-20 | 生化学工业株式会社 | Hyaluronic acid oligosaccharide fractions and drugs containing the same |
| CN109517012B (en) * | 2018-11-13 | 2020-05-22 | 华熙生物科技股份有限公司 | Preparation method of hyaluronic acid oligosaccharide |
-
2022
- 2022-11-22 CN CN202211465206.2A patent/CN115774066B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| High-performance capillary electrophoresis separation of hyaluronan oligosaccharides produced by Streptomyces hyalurolyticus hyaluronate lyase;Francesca Maccari et al.;《Carbohydrate Polymers》;20041231;55-63 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115774066A (en) | 2023-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Desai et al. | Oligosaccharide composition of heparin and low-molecular-weight heparins by capillary electrophoresis | |
| Yang et al. | Disaccharide analysis of glycosaminoglycan mixtures by ultra-high-performance liquid chromatography–mass spectrometry | |
| Nothnagel et al. | Host-pathogen interactions: XXII. A galacturonic acid oligosaccharide from plant cell walls elicits phytoalexins | |
| Lindhardt et al. | Separation of negatively charged carbohydrates by capillary electrophoresis | |
| CN109298112B (en) | Method for measuring content of hyaluronic acid | |
| CN111443149B (en) | Method for measuring content of lysine hydrochloride in sodium hyaluronate composite solution for injection | |
| CN105699578B (en) | A kind of sodium hyaluronate constitutes sugar-type fingerprint analysis method | |
| Kohlhoff et al. | Chitinosanase: A fungal chitosan hydrolyzing enzyme with a new and unusually specific cleavage pattern | |
| Chuang et al. | Chromatographic methods for product-profile analysis and isolation of oligosaccharides produced by heparinase-catalyzed depolymerization of heparin | |
| Rothenhöfer et al. | High performance anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD) for the sensitive determination of hyaluronan oligosaccharides | |
| CN103409484A (en) | Preparation method of superhigh malt syrup | |
| US20240254530A1 (en) | Non-animal chondroitin sulfate oligosaccharide and preparation method thereof | |
| CN114288308A (en) | Hyaluronic acid oligosaccharide composition mainly containing tetrasaccharide and preparation method and application thereof | |
| CN115774066B (en) | Method for analyzing component proportion of ultra-low molecular weight hyaluronic acid | |
| Daniel | [7] Separation of benzoylated oligosaccharides by reversed-phase high-pressure liquid chromatography: Application to high-mannose type oligosaccharides | |
| Wang et al. | Nuclear magnetic resonance quantification for monitoring heparosan K5 capsular polysaccharide production | |
| CN103713057A (en) | Method for degrading heparan sulfate and detecting heparan sulfate disaccharide composition | |
| CN106399428B (en) | A method of it efficiently separates and prepares unimodal molecular weight hyaluronic acid oligosaccharide | |
| Figueiredo et al. | Monitoring of κ-carrageenan depolymerization by capillary electrophoresis and semisynthesis of oligosaccharide alditols | |
| Liu et al. | Analysis of oligomannuronic acids and oligoguluronic acids by high-performance anion-exchange chromatography and electrospray ionization mass spectrometry | |
| Murata et al. | Analysis of hyaluronic acid and chondroitin by high-performance liquid chromatography of the constituent disaccharide units | |
| Delattre et al. | Purification of oligouronides using hollow-fiber membrane functionalised with L-histidine | |
| CN113912745A (en) | Separation and purification method of glycosaminoglycan and preparation method of sulfated oligosaccharide | |
| CN114264741A (en) | Method for identifying whether pig-derived heparin is doped with ruminant heparin | |
| CN111551513A (en) | Method for rapidly determining content of hyaluronic acid in fermentation liquor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |